In this regard, the main strategy to improve the antitumor response in HCC involve the modulation of immunity, through the inhibition of immune checkpoints by the use of monoclonal antibodies directed against molecules such as PD-1 or PD-L1, which enables the activation of the adaptive immune response. This evidence concerns the gene CD274 and hepatocellular carcinoma.